Musella Foundation Report issue

Foundation Phase 1

Organization Overview

First Clinical Trial
2009
NCT00874861
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Musella Foundation for Brain Tumor Research & Information, Inc.

Active Ingredients

Drugs in Phase 1 Trials (2)

poly-iclc (1 trial)

pvsripo (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 1)

Brain Neoplasms (Phase 1)

Ependymoma (Phase 1)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Gliosarcoma (Phase 1)

Medulloblastoma (Phase 1)

Oligodendroglioma (Phase 1)

Rhabdoid Tumor (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2